Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959046 | 1.00 | NPC1 (0.37) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL1963517 | 0.86 | NPC1 (0.36) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL20437123 | 0.85 | NPC1 (0.37) | NPC1MAPTDGAT1HTT | |
| SCHEMBL23624799 | 0.84 | KMT2A (0.41) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL15586644 | 0.84 | NPC1 (0.38) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL31554406 | 0.84 | NPC1 (0.35) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL23611883 | 0.83 | NPC1 (0.37) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL25322201 | 0.83 | DGAT1 (0.36) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL1837871 | 0.83 | MAPT (0.38) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL30509494 | 0.83 | DGAT1 (0.36) | NPC1MAPTCDC7PIM1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177382-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-20240400551-A1 | NEK7 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | NPC1 2009/4885MAPT 3021/4885CDC7 297/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | NPC1 2311/4885MAPT 1770/4885CDC7 425/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | NPC1 348/4885MAPT 436/4885CDC7 39/4885 |
| US-20250177382-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | NPC1 109/4885MAPT 1309/4885CDC7 85/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | NPC1 2009/4885MAPT 3021/4885CDC7 297/4885 |
| US-20240400551-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | NPC1 131/4885MAPT 1535/4885CDC7 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.